John Hadden, a director of Dipexium Pharmaceuticals, Inc., recently acquired 2,190 shares of the company. The buys took place at $0.00 per share (and therefore, likely the result of option or restricted share grants), on April 19, 2017. Hadden now owns 2,190 shares of the company. Hadden operates out of Houston, TX. Some additional info was provided as follows:
Received in exchange for 2,781 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.).
Received in connection with the Merger in exchange for an employee stock option to buy 11,429 shares of PLx Opco Inc. common stock for $9.80 per share.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Dipexium Pharmaceuticals, Inc. makes a similar move, sign up!